Advice

In the absence of a submission from the holder of the marketing authorisation.

paclitaxel (Abraxane®) is not recommended for use within NHS Scotland for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard anthracycline containing therapy is not indicated.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice48KB (PDF)

Download

Medicine details

Medicine name:
paclitaxel (Abraxane)
SMC ID:
556/09
Indication:
Metastatic breast cancer
Pharmaceutical company
Abraxis Bioscience Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
11 May 2009